Increase in intracellular triglyceride synthesis induced by gemfibrozil.
Baldo A., Sniderman AD., Cianflone K.
Laboratory Study, published in Metabolism (1994) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Metabolism (1994)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 8121311
- DOI
- 10.1016/0026-0495(94)90254-2
Abstract (original English)
Gemfibrozil is an effective hypotriglyceridemic agent. Its mechanism of action has not been determined with certainty, but it is generally thought to act by virtue of an effect on lipoprotein lipase. However, this study was designed to test the hypothesis that gemfibrozil directly affects intracellular triglyceride synthesis in peripheral cells, and indeed, when added to the medium, gemfibrozil markedly stimulated triglyceride synthesis in cultured human skin fibroblasts. The effect was concentration-dependent, with a maximum effect at a gemfibrozil concentration of 40 micrograms/mL. A marked increase in triglyceride synthesis was observed when either labeled glucose or labeled fatty acid were added to the medium, indicating that the stimulation was substrate-coordinated. The effect was sustained for hours, with an onset of action within minutes. Lineweaver-Burk plots were constructed, and these revealed no apparent change in Km for either oleate or glucose (8.18 +/- 2.97 v 6.40 +/- 2.10 mumol/L for oleate and 0.113 +/- 0.004 v 0.107 +/- 0.051 mmol/L for glucose, control v gemfibrozil, P = NS). By contrast, there was a significant increase in the maximum triglyceride synthetic rate (Vmax) for both oleate and glucose (14.57 +/- 0.01 v 32.66 +/- 1.85 nmol/mg/4 h for oleate and 67.72 +/- 1.22 v 156.77 +/- 17.61 nmol/mg/4 h for glucose, control v gemfibrozil, P < .025). Given the r
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.